<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Taylor HM</submitter><funding>Medical Research Council</funding><funding>Wellcome Trust</funding><pagination>37-45</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2805293</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(1)</volume><pubmed_abstract>A role for the Plasmodium falciparum cyclic GMP (cGMP)-dependent protein kinase (PfPKG) in gametogenesis in the malaria parasite was elucidated previously. In the present study we examined the role of PfPKG in the asexual blood-stage of the parasite life cycle, the stage that causes malaria pathology. A specific PKG inhibitor (compound 1, a trisubstituted pyrrole) prevented the progression of P. falciparum schizonts through to ring stages in erythrocyte invasion assays. Addition of compound 1 to ring-stage parasites allowed normal development up to 30 h postinvasion, and segmented schizonts were able to form. However, synchronized schizonts treated with compound 1 for > or =6 h became large and dysmorphic and were unable to rupture or liberate merozoites. To conclusively demonstrate that the effect of compound 1 on schizogony was due to its selective action on PfPKG, we utilized genetically manipulated P. falciparum parasites expressing a compound 1-insensitive PfPKG. The mutant parasites were able to complete schizogony in the presence of compound 1 but not in the presence of the broad-spectrum protein kinase inhibitor staurosporine. This shows that PfPKG is the primary target of compound 1 during schizogony and provides direct evidence of a role for PfPKG in this process. Discovery of essential roles for the P. falciparum PKG in both asexual and sexual development demonstrates that cGMP signaling is a key regulator of both of these crucial life cycle phases and defines this molecule as an exciting potential drug target for both therapeutic and transmission blocking action against malaria.</pubmed_abstract><journal>Eukaryotic cell</journal><pubmed_title>The malaria parasite cyclic GMP-dependent protein kinase plays a central role in blood-stage schizogony.</pubmed_title><pmcid>PMC2805293</pmcid><funding_grant_id>MC_U117532067</funding_grant_id><funding_grant_id>066742</funding_grant_id><pubmed_authors>Baker DA</pubmed_authors><pubmed_authors>Hopp CS</pubmed_authors><pubmed_authors>McRobert L</pubmed_authors><pubmed_authors>Taylor HM</pubmed_authors><pubmed_authors>Dluzewski AR</pubmed_authors><pubmed_authors>Sicard A</pubmed_authors><pubmed_authors>Grainger M</pubmed_authors><pubmed_authors>Holder AA</pubmed_authors></additional><is_claimable>false</is_claimable><name>The malaria parasite cyclic GMP-dependent protein kinase plays a central role in blood-stage schizogony.</name><description>A role for the Plasmodium falciparum cyclic GMP (cGMP)-dependent protein kinase (PfPKG) in gametogenesis in the malaria parasite was elucidated previously. In the present study we examined the role of PfPKG in the asexual blood-stage of the parasite life cycle, the stage that causes malaria pathology. A specific PKG inhibitor (compound 1, a trisubstituted pyrrole) prevented the progression of P. falciparum schizonts through to ring stages in erythrocyte invasion assays. Addition of compound 1 to ring-stage parasites allowed normal development up to 30 h postinvasion, and segmented schizonts were able to form. However, synchronized schizonts treated with compound 1 for > or =6 h became large and dysmorphic and were unable to rupture or liberate merozoites. To conclusively demonstrate that the effect of compound 1 on schizogony was due to its selective action on PfPKG, we utilized genetically manipulated P. falciparum parasites expressing a compound 1-insensitive PfPKG. The mutant parasites were able to complete schizogony in the presence of compound 1 but not in the presence of the broad-spectrum protein kinase inhibitor staurosporine. This shows that PfPKG is the primary target of compound 1 during schizogony and provides direct evidence of a role for PfPKG in this process. Discovery of essential roles for the P. falciparum PKG in both asexual and sexual development demonstrates that cGMP signaling is a key regulator of both of these crucial life cycle phases and defines this molecule as an exciting potential drug target for both therapeutic and transmission blocking action against malaria.</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Jan</publication><modification>2025-04-04T11:12:18.045Z</modification><creation>2019-03-27T00:27:53Z</creation></dates><accession>S-EPMC2805293</accession><cross_references><pubmed>19915077</pubmed><doi>10.1128/ec.00186-09</doi><doi>10.1128/EC.00186-09</doi></cross_references></HashMap>